Yi Qian1, Debajyoti Bhowmik2, Nandita Kachru3, Rohini K Hernandez2, Paul Cheng2, Alexander Liede4. 1. Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, USA. yiq@amgen.com. 2. Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, USA. 3. Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA. 4. Amgen Inc., South San Francisco, CA, USA.
Abstract
PURPOSE: This study examined real-world utilization patterns of bone-targeted agents (BTA) in patients with multiple myeloma (MM). METHODS: In this retrospective cohort study, adults with an MM diagnosis recorded in 2012-2014 were identified from electronic health records in the Oncology Services Comprehensive Electronic Records (OSCER) database. Patients received zoledronic acid (ZA) or pamidronate (PA) on/after first MM diagnosis recorded in the study period, had no BTA use in prior 6 months, and were followed through earliest of May 31, 2015 or last clinic visit. Patients with any solid tumor diagnosis were excluded. Time to BTA initiation, compliance (≥ 12 administrations in a year), switching, and non-persistence (switch or ≥ 90-day gap in therapy) were described by agent and follow-up period. RESULTS: Among 9,617 patients with MM, 3,735 (38.8%) received a BTA. Most patients (90.9%) received ZA, with first BTA use generally seen within 3 months of first observed MM diagnosis (ZA 76.1%, PA 75.1%). A minority of ZA (27.4%) and PA (23.0%) patients were compliant in Year 1, with lower compliance in Year 2 (19.8% and 15.6%, respectively). The median time to non-persistence was 16.2 (95% confidence interval [CI] 15.4-17.4) months for ZA and 13.8 (95% CI 11.5-15.4) months for PA. Persistence was 86% at 6 months and 34% at 24 months for ZA, and 77% and 30% for PA, respectively. CONCLUSIONS: These results highlight the possibility of suboptimal prevention of skeletal-related events due to non-compliant dosing and non-persistence after patients initiate BTA therapy.
PURPOSE: This study examined real-world utilization patterns of bone-targeted agents (BTA) in patients with multiple myeloma (MM). METHODS: In this retrospective cohort study, adults with an MM diagnosis recorded in 2012-2014 were identified from electronic health records in the Oncology Services Comprehensive Electronic Records (OSCER) database. Patients received zoledronic acid (ZA) or pamidronate (PA) on/after first MM diagnosis recorded in the study period, had no BTA use in prior 6 months, and were followed through earliest of May 31, 2015 or last clinic visit. Patients with any solid tumor diagnosis were excluded. Time to BTA initiation, compliance (≥ 12 administrations in a year), switching, and non-persistence (switch or ≥ 90-day gap in therapy) were described by agent and follow-up period. RESULTS: Among 9,617 patients with MM, 3,735 (38.8%) received a BTA. Most patients (90.9%) received ZA, with first BTA use generally seen within 3 months of first observed MM diagnosis (ZA 76.1%, PA 75.1%). A minority of ZA (27.4%) and PA (23.0%) patients were compliant in Year 1, with lower compliance in Year 2 (19.8% and 15.6%, respectively). The median time to non-persistence was 16.2 (95% confidence interval [CI] 15.4-17.4) months for ZA and 13.8 (95% CI 11.5-15.4) months for PA. Persistence was 86% at 6 months and 34% at 24 months for ZA, and 77% and 30% for PA, respectively. CONCLUSIONS: These results highlight the possibility of suboptimal prevention of skeletal-related events due to non-compliant dosing and non-persistence after patients initiate BTA therapy.
Entities:
Keywords:
Bone metastasis; Bone-targeted agents; Compliance; Multiple myeloma; Persistence
Authors: Evangelos Terpos; Richard Szydlo; Jane F Apperley; Evdoxia Hatjiharissi; Marianna Politou; John Meletis; Nora Viniou; Xenophon Yataganas; John M Goldman; Amin Rahemtulla Journal: Blood Date: 2003-04-10 Impact factor: 22.113
Authors: Robert A Kyle; Gary C Yee; Mark R Somerfield; Patrick J Flynn; Susan Halabi; Sundar Jagannath; Robert Z Orlowski; David G Roodman; Patricia Twilde; Kenneth Anderson Journal: J Clin Oncol Date: 2007-05-21 Impact factor: 44.544
Authors: Michael Schaapveld; Otto Visser; Sabine Siesling; Cees G Schaar; Sonja Zweegman; Edo Vellenga Journal: Eur J Cancer Date: 2010-01 Impact factor: 9.162
Authors: Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp Journal: Mayo Clin Proc Date: 2003-01 Impact factor: 7.616
Authors: Leah J McGrath; Rohini K Hernandez; Robert Overman; Diane Reams; Alexander Liede; M Alan Brookhart; Elizabeth O'Donnell Journal: Cancer Med Date: 2018-12-08 Impact factor: 4.452